Jason P. Rhodes, Director at Dyne Therapeutics, Inc. (DYN), sold 1,615,106 shares at $24.83 ($39.2M) on 2024-02-28, disclosed to the SEC on 2024-02-28.
Scheduled sale ($39.2M) by Director under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $23.59 | 136,312 | $3.2M | 8.2% |
| 2 | $23.59 | 11,736 | $277K | 0.7% |
| 3 | $23.59 | 11,736 | $277K | 0.7% |
| 4 | $23.59 | 20,205 | $477K | 1.2% |
| 5 | $23.59 | 20,205 | $477K | 1.2% |
| 6 | $23.59 | 136,312 |
| $3.2M |
| 8.2% |
| 7 | $23.98 | 64,783 | $1.6M | 4.0% |
| 8 | $23.98 | 5,580 | $134K | 0.3% |
| 9 | $23.98 | 9,603 | $230K | 0.6% |
| 10 | $23.98 | 9,603 | $230K | 0.6% |
| 11 | $23.98 | 5,580 | $134K | 0.3% |
| 12 | $23.98 | 64,783 | $1.6M | 4.0% |
| 13 | $24.38 | 23,505 | $573K | 1.5% |
| 14 | $24.38 | 23,505 | $573K | 1.5% |
| 15 | $24.38 | 40,455 | $986K | 2.5% |
| 16 | $24.38 | 40,455 | $986K | 2.5% |
| 17 | $24.38 | 272,923 | $6.7M | 17.0% |
| 18 | $24.38 | 272,923 | $6.7M | 17.0% |
| 19 | $24.68 | 25,779 | $636K | 1.6% |
| 20 | $24.68 | 25,779 | $636K | 1.6% |
| 21 | $24.68 | 2,216 | $55K | 0.1% |
| 22 | $24.68 | 3,821 | $94K | 0.2% |
| 23 | $24.68 | 3,821 | $94K | 0.2% |
| 24 | $24.68 | 2,216 | $55K | 0.1% |
| 25 | $24.83 | 152,244 | $3.8M | 9.6% |
| 26 | $24.83 | 13,109 | $325K | 0.8% |
| 27 | $24.83 | 22,567 | $560K | 1.4% |
| 28 | $24.83 | 22,567 | $560K | 1.4% |
| 29 | $24.83 | 152,244 | $3.8M | 9.6% |
| 30 | $24.83 | 13,109 | $325K | 0.8% |
| 31 | $25.25 | 360 | $9K | 0.0% |
| 32 | $25.25 | 2,430 | $61K | 0.2% |
| 33 | $25.25 | 2,430 | $61K | 0.2% |
| 34 | $25.25 | 210 | $5K | 0.0% |
| Total | $24.30 avg | 1,615,106 | $39.2M | 100% |
| Filing → |
| DYN | SELL | 2026-06-30 | $10.7M | — | Filing → |
| DYN | SELL | 2026-06-26 | $5.6M | — | Filing → |
| DYN | SELL | 2026-05-06 | $1.9M | — | Filing → |